carbonthatcarbonthat
← Every company

Oramed Pharmaceuticals Inc Insider Trading

Every director, officer and 10% holder of Oramed Pharmaceuticals Inc has to report each trade in its stock within two business days of making it. This is those filings.

ORMP on carbonthat →
Insiders filing
4
26 reported lines
Open-market buys
0
Open-market sales
2
$942.2K
Net
$942.2K
sold more

Purchases and sales

Open-market trades only — the lines where someone chose to buy or sell at the going price.

InsiderActionValue
Joshua HexterCOO & CBO2026-07-01137K shat $4.46
Sale
$611.4K
Avraham GabayChief Financial Officer2026-07-0173.4K shat $4.51
Sale
$330.7K

Source: SEC Form 4 filings, via EDGAR. A derivative line reports the shares underlying an option rather than stock outstanding, so it is marked and is not comparable with the rest. Value is shares times the reported price, and is blank where the filing priced the transaction at zero — a grant costs its recipient nothing. Insiders sell for reasons that have nothing to do with the company, which is why a sale is not read as a signal on its own.

More on ORMP

Company overviewEverything on ORMP in one place, with the price.SEC filingsWhat ORMP's 8-Ks say happened: results, departures, auditor changes.Executive payWhat ORMP awarded its chief executive, and what it became.Who owns itEvery manager reporting a position in ORMP.Funds holding itWhich funds and ETFs hold ORMP, and how big a bet.PatentsWhat ORMP is filing at the patent office.

Follow Oramed Pharmaceuticals Inc (ORMP) by email

New trades in Oramed Pharmaceuticals Inc (ORMP) by members of Congress, insiders and funds, with the rest of the week's filings. One email a week, free.

Unsubscribe with one click from any email.

Related datasets

PeopleCEOs, investors, public officials and market commentators.SEC FilingsAuditor changes, restatements, departures and results, from 8-Ks.Insider BuyingCluster buys, and chief executives buying their own stock.The InsidersOne page per filer: every company they file against.